Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 313

[177] Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, et al.
Administration of an adenovirus containing the human CFTR cDNA to the respiratory
tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
[178] Boucher RC, Knowles MR, Johnson LG, Olsen JC, Pickles R, Wilson JM, et al. Gene
therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cav-
ity. The University of North Carolina at Chapel Hill. Hum Gene Ther 1994;5:615-39.
[179] Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, et al.
Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis
patients: a phase I clinical trial. Hum Gene Ther 1997;8:15-25.
[180] O'Scaria A, St. George JA, Jiang C, Kaplan JM, Wadsworth SC, Gregory RJ, et al.
Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator
expression in mouse airway epithelium. J Virology 1998;72:7302-7309.
[181] Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, et al. Aerosol and
lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I.
Methods, safety, and clinical implications. Hum Gene Ther 2001;12:1369-82.
[182] Zuckermann JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, et al. A
phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmem-
brane regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene
Ther 1991;10:2973-85.
[183] Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, et al. Repeat
administration of an adenovirus vector encoding cystic fibrosis transmembrane con-
ductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest
1996;97:1504-11.
[184] Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, et al.
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive
administration of a recombinant adenovirus. J Clin Invest 1999;104:1245-55.
[185] Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, et al. A phase I
study of an adeno-associated virus- CFTR gene vector in adult CF patients with mild
lung disease. Hum Gene Ther 1996;7:1145-59.
[186] Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, et al. Efficient and
persistent gene transfer of AAV- CFTR in maxillary sinus. Lancet 1998;351:1702-3.
[187] Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, et al. Liposome
mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.
Nat Med 1995;1:39-46.
[188] Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, et al. A placebo
controlled study of liposome-mediated gene transfer to the nasal epithelium of patients
with cystic fibrosis. Gene Ther 1997;4:199-209.
[189] Porteous DJ, Dorin JR, McLachlan G, Smith HD, Davidson H, Stevenson BJ,
et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR
gene transfer to nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:
210-18.
[190] Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, et al.
Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic
fibrosis. Gene Ther 2000;7:1156-65.
[191] Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, et al. Cationic lipid-
mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a
double-blind placebo-controlled trial. Lancet 1999;353:947-54.
[192] Chadwick SL, Kingston HD, Stern M, Cook RM, O'Connor BJ, Lukasson M, et al.
Safety of a single aerosol administration of escalating doses of the cationic lipid